Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma

Cancers - Switzerland
doi 10.3390/cancers12010023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Clinical Liver Disease
Hepatology
2019English

Direct-Acting Antivirals and Recurrence of Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2017English

Direct-Acting Antiviral Therapy for HCV Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Gastroenterology
HepatologyGastroenterology
2019English

Pro: Direct-Acting Agents Are Associated With Occurrence and Recurrence of Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2017English

The Risk of Hepatocellular Carcinoma Is Increased in Hepatitis C Virus Patients Treated With Interferonfree Direct-Acting Antiviral-Based Therapy: True or False?

Biomedical Journal of Scientific & Technical Research
2018English

De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Hepatology
MedicineHepatology
2018English

The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-Infected Patients Treated With Direct-Acting Antivirals With and Without Pegylated Interferon: A Belgian Experience

Journal of Viral Hepatitis
VirologyHepatologyInfectious Diseases
2017English

Two Cases of Hepatocellular Carcinoma Occurring Immediately After Direct-Acting Antiviral Agents Against Hepatitis C Virus

Internal Medicine
Internal MedicineMedicine
2019English

No Evidence for Higher Rates of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment: A Meta-Analysis

Hepatoma Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy